Akbar A N, Fitzgerald-Bocarsly P A, de Sousa M, Giardina P J, Hilgartner M W, Grady R W
J Immunol. 1986 Mar 1;136(5):1635-40.
We have investigated the natural killer (NK) activity of both fractionated (Percoll density gradient) and unfractionated mononuclear cells from patients with beta-thalassemia major who are iron overloaded as a consequence of chronic transfusion therapy. These patients were found to have significantly decreased NK activity against K562 targets at all effector:target ratios tested (p less than 0.001). Both splenectomized and nonsplenectomized patients had normal proportions of Leu-11b-staining (NK) cells. Since they had normal to elevated absolute white cell and lymphocyte counts, a change in the absolute number of NK cells could not account for the decreased killing. We also found that the decrease in NK activity was transfusion related (r = -0.603, p less than 0.005). To determine whether or not this decrease in NK activity could be related to iron overload, we preincubated patient effector cells with desferrioxamine (DFO) or 2,3-dihydroxybenzoic acid (DHB) for 6 hr before addition of K562 targets. Both of these iron-chelating agents consistently increased the NK activity of cells from thalassemia patients. DHB had the greater effect, being able to increase patient NK activity to virtually normal levels. On the other hand, preincubation of cells from normal controls with DHB caused only a slight increase in NK activity, while similar treatment with DFO had little or no effect. When target cells were preincubated with the chelating agents before addition of either normal or patient effector cells, no change in cytotoxicity was seen, demonstrating that the chelating agents act at the effector cell level. Furthermore, if the chelating agents were saturated with iron prior to preincubation with the effectors, no increase in the cytotoxicity of thalassemic NK cells was observed. These results indicate that thalassemia patients have a reversible, transfusion-related decrease in NK function which may arise as a consequence of iron overload.
我们研究了重型β地中海贫血患者经慢性输血治疗导致铁过载后,其经分离的(Percoll密度梯度法)和未分离的单核细胞的自然杀伤(NK)活性。发现在所有测试的效应细胞与靶细胞比例下,这些患者针对K562靶标的NK活性均显著降低(p小于0.001)。脾切除和未脾切除的患者Leu-11b染色(NK)细胞比例均正常。由于他们的绝对白细胞和淋巴细胞计数正常或升高,NK细胞绝对数量的变化不能解释杀伤活性的降低。我们还发现NK活性的降低与输血有关(r = -0.603,p小于0.005)。为了确定这种NK活性的降低是否与铁过载有关,我们在加入K562靶标之前,将患者的效应细胞与去铁胺(DFO)或2,3-二羟基苯甲酸(DHB)预孵育6小时。这两种铁螯合剂均持续增加地中海贫血患者细胞的NK活性。DHB的效果更佳,能够将患者的NK活性提高到几乎正常的水平。另一方面,用DHB预孵育正常对照细胞仅导致NK活性略有增加,而用DFO进行类似处理则几乎没有作用或没有效果。当在加入正常或患者效应细胞之前将靶细胞与螯合剂预孵育时,未观察到细胞毒性的变化,这表明螯合剂作用于效应细胞水平。此外,如果螯合剂在与效应细胞预孵育之前用铁饱和,则未观察到地中海贫血NK细胞的细胞毒性增加。这些结果表明,地中海贫血患者的NK功能存在与输血相关的可逆性降低,这可能是铁过载的结果。